Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

NCT01383759 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Light Chain Deposition Disease (LCDD or MIDD)
Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
Monoclonal Immunoglobulin Deposition Disease (MIDD)
Amyloidosis

Interventions

DRUG: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]